135 related articles for article (PubMed ID: 37381749)
21. Characteristics of Nosocomial Infections in Children Screened for SARS-CoV-2 Infection in China.
Shen J; Sun J; Zhao D; Li S; Xiao W; Cai X; Yan J; Zhu W; Guo Q; Wen X; Wu J; Shi X; Jiang D; Huang J; Luo J; Chen H; Hong Y; Ma W; Liu G; Yang H; Wang Q; Song Y; Lin J; Sun X; Li P
Med Sci Monit; 2020 Dec; 26():e928835. PubMed ID: 33335084
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children and Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain.
Brotons P; Launes C; Buetas E; Fumado V; Henares D; de Sevilla MF; Redin A; Fuente-Soro L; Cuadras D; Mele M; Jou C; Millat P; Jordan I; Garcia-Garcia JJ; Bassat Q; Muñoz-Almagro C;
Clin Infect Dis; 2021 Jun; 72(12):e970-e977. PubMed ID: 33180914
[TBL] [Abstract][Full Text] [Related]
23. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant.
Liu X; Chen M; Zhou Z; Chen D; Mo J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):344-351. PubMed ID: 35545327
[TBL] [Abstract][Full Text] [Related]
24. [Measurement of bile acid N-acetylglucosaminides in serum and urine of patients with chronic liver diseases during ursodeoxycholic acid treatment].
Kimura A; Nakamura K; Makino I
Nihon Shokakibyo Gakkai Zasshi; 1995 Mar; 92(3):224-32. PubMed ID: 7731091
[TBL] [Abstract][Full Text] [Related]
25. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
26. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
Kertes J; Shapiro Ben David S; Engel-Zohar N; Rosen K; Hemo B; Kantor A; Adler L; Shamir Stein N; Mizrahi Reuveni M; Shahar A
Clin Infect Dis; 2023 Feb; 76(3):e126-e132. PubMed ID: 35904210
[TBL] [Abstract][Full Text] [Related]
27. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.
Xu X; Wu H; Jin G; Huang J; Li J; Zhou J; Cao M; Sun D; Zhang W; Peng W; Pu Y; Chen C; Sun Y; Yang H; Zhou S; Fang B
Phytomedicine; 2023 Mar; 111():154665. PubMed ID: 36641977
[TBL] [Abstract][Full Text] [Related]
29. Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection.
Prayitno K; Bhat M
Gastroenterology; 2023 May; 164(6):1019-1020. PubMed ID: 36681157
[No Abstract] [Full Text] [Related]
30. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.
Ruutu T; Eriksson B; Remes K; Juvonen E; Volin L; Remberger M; Parkkali T; Hägglund H; Ringdén O;
Blood; 2002 Sep; 100(6):1977-83. PubMed ID: 12200355
[TBL] [Abstract][Full Text] [Related]
31. [Epidemiological features of severe acute respiratory syndrome coronavirus 2 infection in children in Shijiazhuang, China: an analysis of 133 cases].
Lu SK; Niu B; Ji LL; Liu JH; Shuai JF
Zhongguo Dang Dai Er Ke Za Zhi; 2021 May; 23(5):456-459. PubMed ID: 34020733
[TBL] [Abstract][Full Text] [Related]
32. [Characteristics of SARS-CoV-2 Omicron infection in children imported from Hong Kong].
Ma WJ; Wang XS; Tian H; Zhu YF; Wei ZQ; Xu J; Zhu QR; Zeng M
Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):539-544. PubMed ID: 35658359
[No Abstract] [Full Text] [Related]
33. COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020.
Pathak EB; Salemi JL; Sobers N; Menard J; Hambleton IR
J Public Health Manag Pract; 2020; 26(4):325-333. PubMed ID: 32282440
[TBL] [Abstract][Full Text] [Related]
34. Limited role of children in transmission of SARS-CoV-2 virus in households-Immunological analysis of 26 familial clusters.
Sieber J; Schmidthaler K; Kopanja S; Weseslindtner L; Stiasny K; Götzinger F; Graf A; Krotka P; Hoz J; Schoof A; Dwivedi V; Frischer T; Szépfalusi Z
Pediatr Allergy Immunol; 2023 Jan; 34(1):e13913. PubMed ID: 36705043
[TBL] [Abstract][Full Text] [Related]
35. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease.
Narkewicz MR; Smith D; Gregory C; Lear JL; Osberg I; Sokol RJ
J Pediatr Gastroenterol Nutr; 1998 Jan; 26(1):49-55. PubMed ID: 9443120
[TBL] [Abstract][Full Text] [Related]
36. Croup as a Manifestation of SARS-CoV-2 Omicron Variant Infection in Young Children.
Choi YY; Kim YS; Lee SY; Sim J; Choe YJ; Han MS
J Korean Med Sci; 2022 May; 37(20):e140. PubMed ID: 35607737
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children's medical center in Shanghai, China.
Shen N; Wu YF; Chen YW; Fang XY; Zhou M; Wang WY; Tang MY; Pan QH; Ma J; Zhang H; Cao Q
World J Pediatr; 2023 Jan; 19(1):87-95. PubMed ID: 36251118
[TBL] [Abstract][Full Text] [Related]
38. [Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases].
Zhang PP; Guo YT; Chu YQ; Ji QI; Lian Y; Li W; Yao LN
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):736-741. PubMed ID: 35894186
[TBL] [Abstract][Full Text] [Related]
39. Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant.
Butt AA; Dargham SR; Loka S; Shaik RM; Chemaitelly H; Tang P; Hasan MR; Coyle PV; Yassine HM; Al-Khatib HA; Smatti MK; Kaleeckal AH; Latif AN; Zaqout A; Almaslamani MA; Al Khal A; Bertollini R; Abou-Samra AB; Abu-Raddad LJ
Clin Infect Dis; 2022 Aug; 75(1):e361-e367. PubMed ID: 35404391
[TBL] [Abstract][Full Text] [Related]
40. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
